The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity
Open accessAbstract
The high prevalence of pre-existing immunity to adenovirus serotype 5 (Ad5) in human populations may substantially limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for HIV-1 and other pathogens. A potential solution to this problem is to use vaccine vectors derived from adenovirus (Ad) serotypes that are rare in humans, such as Ad35. However, cross-reactive immune responses between heterologous Ad serotypes have been described and could prove a major limitation of this strategy. In particular, the extent of immunologic cross-reactivity between Ad5 and Ad35 has not previously been determined. In this study we investigate the impact of pre-existing anti-Ad5 immunity on the immunogenicity of candidate rAd5 and rAd35 vaccines expressing SIV Gag in mice. Anti-Ad5 immunity at levels typically found in humans dramatically blunted the immunogenicity of rAd5-Gag. In contrast, even high levels of anti-Ad5 immunity did not substantially suppress Gag-specific cellular immune responses elicited by rAd35-Gag. Low levels of cross-reactive Ad5/Ad35-specific CD4+ T lymphocyte responses were observed, but were insufficient to suppress vaccine immunogenicity. These data demonstrate the potential utility of Ad35 as a candidate vaccine vector that is minimally suppressed by anti-Ad5 immunity. Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 2×
“Tetrameric D/AL11 complexes were constructed essentially as previously described (4, 19) and were used to quantitate the emergence of AL11-specific CD8 T lymphocyte responses elicited by rAd5-Gag and rAd35-Gag in mice with or without anti-Ad5 immunity.”
MethodSelf-citationIsolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Shiver, J. W., Fu, T.-M., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z.-Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,176
Self-citationCD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 792
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Self-citationRoelvink, P. W., Lizonova, A., Lee, J. G. M., Li, Y., Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi, I., & Wickham, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7909-7915.1998 · Cited by 654
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Self-citationRoelvink, P. W., Lee, G. M., Einfeld, D. A., Kovesdi, I., & Wickham, T. J. (1999) · Science · doi:10.1126/science.286.5444.1568 · Cited by 406
Casimiro, D. R., Chen, L., Fu, T.-M., Evans, R. K., Caulfield, M. J., Davies, M.-E., Tang, A., Chen, M., Huang, L., Harris, V., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6305-6313.2003 · Cited by 400
Replication-Defective Vector Based on a Chimpanzee Adenovirus
Farina, S. F., Gao, G.-P., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. J., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11603-11613.2001 · Cited by 272
A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag
Fitzgerald, J. C., Gao, G.-P., Reyes-Sandoval, A., Pavlakis, G. N., Xiang, Z. Q., Wlazlo, A. P., Giles-Davis, W., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1416 · Cited by 216
Mastrangeli, A., Harvey, B.-G., Yao, J., Wolff, G., Kovesdi, I., Crystal, R. G., & Falck-Pedersen, E. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.1-79 · Cited by 204
Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting
Yang, Z.-Y., Wyatt, L. S., Kong, W.-P., Moodie, Z., Moss, B., & Nabel, G. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.799-803.2003 · Cited by 204
Self-citationMack, C. A., Song, W.-R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B.-G., Magovern, C. J., Isom, O. W., Rosengart, T., Falck-Pedersen, E., et al. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.1-99 · Cited by 192
Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease
Havenga, M. J. E., Lemckert, A. A. C., Ophorst, O. J. A. E., van Meijer, M., Germeraad, W. T. V., Grimbergen, J., van den Doel, M. A., Vogels, R., van Deutekom, J., Janson, A. A. M., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4612-4620.2002 · Cited by 192
Self-citationSprangers, M. C., Lakhai, W., Koudstaal, W., Verhoeven, M., Koel, B. F., Vogels, R., Goudsmit, J., Havenga, M. J. E., & Kostense, S. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5046-5052.2003 · Cited by 188
Self-citationProspects for Vaccine Protection Against HIV-1 Infection and AIDS
Letvin, N. L., Barouch, D. H., & Montefiori, D. C. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.081501.094854 · Cited by 179
Self-citationRea, D., Havenga, M. J. E., van den Assem, M., Sutmuller, R. P. M., Lemckert, A., Hoeben, R. C., Bout, A., Melief, C. J. M., & Offringa, R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.5236 · Cited by 158
Self-citationFlexibility of the Adenovirus Fiber Is Required for Efficient Receptor Interaction
Wu, E., Pache, L., Von Seggern, D. J., Mullen, T.-M., Mikyas, Y., Stewart, P. L., & Nemerow, G. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7225-7235.2003 · Cited by 158
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
Kostense, S., Koudstaal, W., Sprangers, M., Weverling, G. J., Penders, G., Helmus, N., Vogels, R., Bakker, M. E., Berkhout, B., Havenga, M. J. E., et al. (2004) · AIDS · doi:10.1097/00002030-200405210-00019 · Cited by 156
Self-citationCircumventing the immune response to adenovirus-mediated gene therapy.
Kass-Eisler, A., Leinwand, L. A., Gall, J. G. D., Bloom, B., & Falck-Pedersen, E. (1996) · PubMed · Cited by 134
Improved Adenovirus Vectors for Infection of Cardiovascular Tissues
Havenga, M. J. E., Lemckert, A. A. C., Grimbergen, J. M., Vogels, R., Huisman, L. G. M., Valerio, D., Bout, A., & Quax, P. H. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.7.3335-3342.2001 · Cited by 133
Self-citationShayakhmetov, D. M., Li, Z.-Y., Ternovoi, V. V., Gaggar, A., Gharwan, H., & Lieber, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3712-3723.2003 · Cited by 126
Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Chakrabarti, B. K., Xu, L., Nabel, G. J., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8729-8735.2003 · Cited by 122
Self-citationMizuguchi, H., & Hayakawa, T. (2002) · Gene · doi:10.1016/s0378-1119(02)00410-9 · Cited by 119
The Adenovirus Capsid Protein Hexon Contains a Highly Conserved Human CD4 + T-Cell Epitope
Olive, M., Eisenlohr, L. C., Flomenberg, N., Hsu, S. H., & Flomenberg, P. R. (2002) · Human Gene Therapy · doi:10.1089/104303402320138952 · Cited by 117
Pinto, A. R., Fitzgerald, J. C., Giles‐Davis, W., Gao, G. P., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6774 · Cited by 113
Ovine Adenovirus Vectors Overcome Preexisting Humoral Immunity against Human Adenoviruses In Vivo
Hofmann, C., Löser, P., Cichon, G., Arnold, W., Both, G. W., & Strauss, M. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6930-6936.1999 · Cited by 108
Heemskerk, B., Veltrop‐Duits, L. A., van Vreeswijk, T., ten Dam, M. M., Heidt, S., Toes, R. E. M., van Tol, M. J. D., & Schilham, M. W. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6562-6566.2003 · Cited by 90
Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector
Sakurai, F., Mizuguchi, H., & Hayakawa, T. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301959 · Cited by 88
Development of Replication-Defective Herpes Simplex Virus Vectors
Krisky, D. M., Marconi, P., Goins, W. F., & Glorioso, J. C. (2003) · Humana Press eBooks · doi:10.1385/0-89603-484-4:79 · Cited by 71
Cited by
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Self-citationHexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 491
Self-citationImmune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., et al. (2009) · Nature · doi:10.1038/nature07469 · Cited by 452
Self-citation
Metadata
- Authors
- Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., Korioth-Schmitz, B., Newberg, M. H., Gorgone, D. A., Lifton, M. A., Panicali, D. L., Nabel, G. J., Letvin, N. L., & Goudsmit, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-05
- Volume
- 172
- Issue
- 10
- Pages
- 6290-6297
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1924636867
- Cited by
- 383
- References
- 31
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.